Review
Open access
Aug 2026
Clinical landscape of human pluripotent stem cell-derived cardiomyocyte therapy.
The pathophysiological rationale for cell-based therapy in heart failure with reduced ejection fraction is summarized, and the preclinical foundations of distinct hPSC-derived product formats are examined, including cell suspensions, epicardial sheets, engineered heart muscle, and cardiac spheroids, each with distinct tradeoffs and translational considerations.
Byron W H Mui, E. Neofytou, Joseph C. Wu
· Cell Reports Medicine · 0 citations